The subject of this publication is the conclusion of non-exclusive discount agreements pursuant to Section 130a (8 of the German Civil Code V) for medicines containing the active substance bimatoprost (ATC code according to WHO: S01EE03). The contract is concluded within the framework of a so-called open-house model, i.e. a contract is open to all interested pharmaceutical companies within the participation period provided that they meet and accept the requirements for participation. As a result, individual contract negotiations are not conducted and there is no (delivery) exclusivity. It should be pointed out that the quantity purchased is unknown, as this depends on the demand and development of the number of policyholders, on the prescribing behaviour of doctors and the dispensing and stocking behaviour of public pharmacies. Minimum purchase quantities are therefore not guaranteed. For more information, please see point II.2.4) of the announcement.

Interested pharmaceutical companies can download the participation documents via the project space of the German Procurement Portal (DTVP). To do this, an application for access to the project space is first required. After activation by the client, the participation documents can then be accessed. The documents to be submitted result from the documents "Cover letter" and "Explanations of the terms of the contract" stored in the project room. Communication, including the transmission of participation documents, takes place electronically via the DTVP procurement portal; Details can be found in the aforementioned documents. Any information to the contrary in the contract notice is due to technical reasons and does not claim to be binding.

Applications for participation can be submitted for the first time until 06.06.2023.

All other submission deadlines can be found in the appendix "Submission deadlines" stored in the project room. If the day of the submission deadline falls on a Saturday, Sunday or nationwide public holiday, the next working day shall take the place of such a day. In the event of late receipt, the submitted requests to participate will be taken into account at the next submission deadline. The client reserves the right, in compliance with the principles of transparency and equal treatment, to request the pharmaceutical companies to submit, complete or correct missing, incomplete or incorrect documents (in particular declarations, information and evidence) (additional claim). The documents must be submitted by the pharmaceutical company at the request of the client within a period determined according to the calendar. If the requested documents are not submitted within the deadline, the request to participate can be excluded or only considered at the next submission deadline.

The discount agreement ends, regardless of the date of conclusion of the contract, no later than 30.06.2025.

The client reserves the right to terminate the open house procedure prematurely, in particular in the event of the conclusion of exclusive discount agreements; in this case, the discount agreements already concluded end in accordance with the contractual provisions. According to the experience of the client, exclusive discount agreements usually come into force 8 to 12 months after publication of the relevant contract notice in the supplement to the Official Journal of the European Union.